Pfizer and BioNTech have applied for emergency approval for their Covid-19 vaccine

Just last week, Pfizer and BioNTech revealed that their experimental Covid-19 vaccine, called BNT162b2, was at least 90 percent effective in an early analysis. On Wednesday, the pharmaceutical and biotech companies reported that their vaccine was even more effective after it cleared more clinical trial benchmarks for safety and efficacy. And on Friday, they said they are requesting an emergency use authorization (EUA) from the Food and Drug Administration.

If granted an EUA, the BNT162b2 vaccine could be administered to certain high-risk groups in the United States — most likely...